Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)

Hiroyoshi Suzuki

Sakura, JP 
Advanced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Sakura, JP 
OverviewLocationsClinical Research

Overview

Hiroyoshi Suzuki practices in Sakura, Japan. Suzuki is rated as an Advanced expert by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). Their top areas of expertise are Prostate Cancer, Dysembryoplastic Neuroepithelial Tumors (DNET), Hyperaldosteronism, Lithotripsy, and Prostatectomy.

Their clinical research consists of co-authoring 347 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Dysembryoplastic Neuroepithelial Tumors (DNET).

Locations

Sakura, 2858741, Japan
Other Locations
Sakura, 2858741, Japan
Shibata, Japan
Sendai, Japan
Sapporo, 0600818, Japan
Mito, Japan
Tobo, Japan
Gifu-shi, Japan
Osaka, Japan
Wakayama, Japan
Chiba, 2858741, Japan
Inashiki, 3000393, Japan
Komaki, 4850852, Japan
Chuo, 2608670, Japan
St Marianna University School of Medicine
Kawasaki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase 1 Study of Abemaciclib in Combination With Other Anti-Cancer Therapy in Japanese Patients With Advanced Cancer
A Phase 1 Study of Abemaciclib in Combination With Other Anti-Cancer Therapy in Japanese Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: September 21, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

347 Total Publications

Carbon-Ion Radiotherapy for Prostate Cancer in Patients with a History of Surgery for Benign Prostatic Hyperplasia.
Carbon-Ion Radiotherapy for Prostate Cancer in Patients with a History of Surgery for Benign Prostatic Hyperplasia.
Journal: Cancers
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Suzuki's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile